Linomide
CAS: 84088-42-6
Rif. 3D-JDA08842
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione |
Informazioni sul prodotto
- 1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide
- 1,2-Dihydro-4-hydroxy-N,N-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide
- 2-hydroxy-N,1-dimethyl-4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide
- 3-Quinolinecarboxamide, 1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-
- 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
- Abr 212616
- Fcf 89
- Ls 2616
- N-Methyl-N-phenyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide
- Pnu 212616
- Vedi altri sinonimi
- Roquinimex
Linomide is a drug that inhibits the angiogenic process and prevents the growth of cancer cells. It has been shown to be effective against renal cell cancer in vitro assays and in animal models. Linomide is also effective against autoimmune diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. In vitro assays have shown that linomide can inhibit the growth of several types of human cancers, including breast cancer, prostate cancer, and bowel cancer. This drug has also been shown to be an inhibitor of basic fibroblast growth factor (bFGF) receptor kinase activity and neuronal death.